Differential protein acetylation induced by novel histone deacetylase inhibitors

Biochemical and Biophysical Research Communications

Volumn 325, Issue 3, 2004, Pages 683-690

  Glaser, K B ^a   Li, J ^a   Pease, L J ^a   Staver, M J ^a   Marcotte, P A ^a   Guo, J ^a   Frey, R R ^a   Garland, R B ^a   Heyman, H R ^a   Wada, C K ^a   Vasudevan, A ^a   Michaelides, M R ^a   Davidsen, S K ^a   Curtin, M L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Acetylated histones; Acetylated tubulin; Chromatin remodeling; Histone deacetylase; Isozyme selectivity; Suberoylanilide hydroxamic acid; Trichostatin A; Tubulin deacetylase

Indexed keywords

ALPHA TUBULIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ISOENZYME; SUCCINIMIDE DERIVATIVE;

ACETYLATION; ARTICLE; CELL ASSAY; CONTROLLED STUDY; ENZYME ISOLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROSARCOMA; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS;

EID: 8544225755     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.10.082     Document Type: Article

References (40)

1. J. Davie, and V. Spencer Signal transduction pathways and the modification of chromatin structure Prog. Nucleic Acid Res. 65 2001 299 340
2. A. Wolffe Chromatin remodeling: why it is important in cancer Oncogene 20 2001 2988 2990
3. R. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat. Rev. 1 2002 287 299
4. P. Marks, V. Richon, and R. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 2000 1210 1216
5. F. Grignani, S. Dematteis, C. Nervi, L. Tomassoni, V. Gelmetti, M. Cioce, M. Fanelli, M. Ruthardt, F. Ferrara, I. Zamir, C. Seiser, M. Lazar, S. Minucci, and P. Pelicci Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia Nature 391 1998 815 818
6. R. Lin, L. Nagy, S. Inoue, W. Shao, W. Miller, and R. Evans Role of histone deacetylase complex in acute promyelocytic leukemia Nature 391 1998 811 814
7. R. Warrell, L.-Z. He, V. Richon, E. Calleja, and P. Pandolfi Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J. Natl. Cancer Inst. 90 1998 1621 1625
8. P. Driever, J. Wolff, and A. Pekrun Valproic acid treatment of glioblastoma multiforme in a child Pediatr. Blood Cancer 43 2004 181
9. W. Kelly, O. O'Connor, and P. Marks Histone deacetylase inhibitors: from target to clinical trials Expert Opin. Investig. Drugs 11 2002 1695 1713
10. S. Gray, and T. Ekstrom The human histone deacetylase family Exp. Cell Res. 262 2001 75 83
11. A.d. Ruijter, A.v. Gennip, H. Caron, S. Kemp, and A.v. Kuilenburg Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem. J. 370 2003 737 749
12. J. Landry, A. Sutton, S. Tafrov, R. Heller, J. Stebbins, L. Pillus, and R. Sternglanz The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases Proc. Natl. Acad. Sci. USA 97 2000 5807 5811
13. S.-I. Imai, C. Armstrong, M. Kaeberlein, and L. Guarente Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase Nature 403 2002 795 800
14. J. Luo, A. Nikolaev, S.-I. Imai, D. Chen, F. Su, A. Shiloh, L. Guarente, and W. Gu Negative control of p53 by Sir2α promotes cell survival under stress Cell 107 2001 137 148
15. SIRT1 functions as an NAD-dependent p53 deacetylase Cell 107 2001 149 159
16. K. Glaser, J. Li, M. Aakre, D. Morgan, G. Sheppard, K. Stewart, J. Pollock, P. Lee, C. O'Connor, S. Anderson, D. Mussatto, C. Wegner, and H. Moses Transforming growth factor β mimetics: discovery of 7-[4-(4-cyanophenyl) phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase Mol. Cancer Ther. 1 2002 759 768
17. B. Bernstein, T. Tong, and S. Schreiber Genomewide studies of histone deacetylase function in yeast Proc. Natl. Acad. Sci. USA 97 2000 13708 13713
18. K. Glaser, J. Li, M. Staver, R.-Q. Wei, D. Albert, and S. Davidsen Role of class I and class II histone deacetylases in carcinoma cells using siRNA Biochem. Biophys. Res. Commun. 310 2003 529 536
19. J. Li, M. Staver, M. Curtin, J. Holms, R. Frey, R. Edalji, R. Smith, M. Michaelides, S. Davidsen, and K. Glaser Expression and functional characterization of recombinant human HDAC1 and HDAC3 Life Sci. 74 2004 2693 2705
20. M. Curtin, and K. Glaser Histone deacetylase inhibitors: the Abbott experience Curr. Med. Chem. 10 2003 2373 2392
21. W. Fischle, F. Dequiedt, M. Fillion, M. Hendzel, W. Voelter, and E. Verdin Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo J. Biol. Chem. 276 2001 35826 35835
22. W. Fischle, F. Dequiedt, M. Hendzel, M. Guenther, M. Lazar, W. Voelter, and E. Verdin Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR Mol. Cell 9 2002 45 57
23. D. Steinman, M. Curtin, R. Garland, S. Davidsen, H. Heyman, J. Holms, D. Albert, T. Magoc, I. Nagy, P. Marcotte, J. Li, D. Morgan, C. Hutchins, and J. Summers The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors Bioorg. Med. Chem. Lett. 8 1998 2087 2092
24. M. Curtin, R. Garland, H. Heyman, R. Frey, M. Michaelides, J. Li, L. Pease, K. Glaser, P. Marcotte, and S. Davidsen Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC) Bioorg. Med. Chem. Lett. 12 2002 2919 2923
25. C. Wada, R. Frey, Z. Ji, M. Curtin, R. Garland, J. Holms, J. Li, L. Pease, J. Guo, K. Glaser, P. Marcotte, P. Richardson, S. Murphy, J. Bouska, P. Tapang, T. Magoc, D. Albert, S. Davidsen, and M. Michaelides α-keto amides as inhibitors of histone deacetylase Bioorg. Med. Chem. Lett. 13 2003 3331 3335
26. K. Glaser, M. Staver, J. Waring, J. Stender, R. Ulrich, and S. Davidsen Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol. Cancer Ther. 2 2003 151 163
27. J. Wong, R. Hong, and S. Schreiber Structural biasing elements for in-cell histone deacetylase paralog selectivity J. Am. Chem. Soc. 125 2003 5586 5587
28. M. Finnin, J. Donigian, A. Cohen, V. Richon, R. Rifkind, P. Marks, R. Breslow, and N. Pavletich Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188 193
29. B. Jose, S. Okamura, T. Kato, N. Nishino, Y. Sumida, and M. Yoshida Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α-tubulin sequence Bioorg. Med. Chem. 12 2004 1351 1356
30. T. Wu, C. Hassig, Y. Wu, S. Ding, and P. Schultz Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group Bioorg. Med. Chem. Lett. 14 2004 449 453
31. R. Furumai, Y. Komatsu, N. Nishino, S. Khochbin, M. Yoshida, and S. Horinouchi Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin Proc. Natl. Acad. Sci. USA 98 2001 87 92
32. R. Furumai, A. Matsuyama, N. Kobashi, K.-H. Lee, M. Nishiyama, H. Nokajima, A. Tanaka, Y. Komatsu, M. Yoshida, and S. Horinouchi FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res. 62 2002 4916 4921
33. N. Nishino, B. Jose, S. Okamura, S. Ebisusaki, T. Kato, Y. Sumida, and M. Yoshida Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases Org. Lett. 5 2003 5079 5082
34. S. Sternson, J. Wong, C. Grozinger, and S. Schreiber Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin Org. Lett. 3 2001 4239 4242
35. K. Koeller, S. Haggarty, B. Perkins, I. Leykin, J. Wong, M.-C. Kao, and S. Schreiber Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation Chem. Biol. 10 2003 397 410
36. A. Matsuyama, T. Shimazu, Y. Sumida, A. Saito, Y. Yoshimatsu, D. Seigneurin-Berny, H. Osada, Y. Komatsu, N. Nishino, S. Khochbin, S. Horinouchi, and M. Yoshida In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation EMBO J. 21 2002 6820 6831
37. M. Blagosklonny, R. Robey, D. Sackett, L. Du, F. Traganos, Z. Darzynkiewicz, T. Fojo, and S. Bates Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol. Cancer Ther. 1 2002 937 941
38. C. Hubbert, A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X.-F. Wang, and T.-P. Yao HDAC6 is a microtubule-associated deacetylase Nature 417 2002 455 458
39. R. Warrener, H. Beamish, A. Burgess, N. Waterhouse, N. Giles, D. Fairlie, and B. Gabrielli Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints FASEB J. 17 2003 1550 1552
40. S. Haggarty, K. Koeller, J. Wong, C. Grozinger, and S. Schreiber Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc. Natl. Acad. Sci. USA 100 2003 4389 4394